The Latest Breaking News from GSK

You might not have heard of respiratory syncytial virus, or RSV. But it caused more than 100,000 global deaths in 2019, making it a leading cause of death in children under one year old.

Hybrid and flexible working is offered at most FTSE 100 companies, survey results suggest

Here is the full list of respondents and their feedback to a Evening Standard survey looking at weekly working patterns, writes Joanna Hodgson

A glitch in a law may make it difficult for children from low-income families to get the new RSV vaccine

Unite chiefs say their members are determined to get 'what they are owed' in bonus payments row.

The pharmaceutical industry is well-positioned for significant growth in the near future, given the growing demand for medicines and increasing R&D activities. Given the industry's inelastic demand, fundamentally strong pharma stocks AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and GSK plc (GSK) might be solid long-term investments. Continue reading….

Emma Walmsley says ambition to be pharma superpower at risk unless improvements made in key areas

GSK stock and NVO stock rose Wednesday, though both beat forecasts. Novartis stock skidded on lighter-than-expected sales.

Interest rates are today expected to rise another 0.5% to 4% as the Bank of England continues the fight against inflation with its 10th increase in a row.

The Food and Drug Administration granted Moderna's experimental RSV vaccine an expedited review, but Moderna stock dipped Monday.

Experts are calling gepotidacin a massive step forwards in the fight against resistance to antibiotics